Morphic Holding
General Information | |
Business: |
We are a biopharmaceutical company applying our proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. To date, no oral small-molecule integrin therapies have been approved by the U.S. Food and Drug Administration, or FDA. Despite significant unsuccessful efforts, we believe tremendous untapped potential remains for us to develop oral integrin therapies. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 65 |
Founded: | 2014 |
Contact Information | |
Address | 35 Gatehouse Drive, A2, Waltham, MA 02451, US |
Phone Number | (781) 996-0955 |
Web Address | http://www.morphictx.com |
View Prospectus: | Morphic Holding |
Financial Information | |
Market Cap | $443.9mil |
Revenues | $9.4 mil (last 12 months) |
Net Income | $-23.9 mil (last 12 months) |
IPO Profile | |
Symbol | MORF |
Exchange | NASDAQ |
Shares (millions): | 6.0 |
Price range | $15.00 - $15.00 |
Est. $ Volume | $90.0 mil |
Manager / Joint Managers | Jefferies/ Cowen and Company/ BMO Capital Markets/ Wells Fargo Securities |
CO-Managers | - |
Expected To Trade: | 6/27/2019 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |